Prelude Therapeutics (PRLD) Cash from Financing Activities (2019 - 2026)
Prelude Therapeutics (PRLD) posted Cash from Financing Activities of -$314000.0 for Q1 2026, down 101.26% sequentially from $24.9 million in Q4 2025, and down 96.25% YoY from -$8.4 million in Q1 2025.
Powered by 
Analysis
Prelude Therapeutics (PRLD) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Cash from Financing Activities for 8 years, with the latest figure at -$314000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 96.25% year-over-year to -$314000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.7 million (up 9371.43% YoY) and the FY2025 annual result came in at $24.8 million, up 20780.0% from the prior year.
- Cash from Financing Activities eased to -$314000.0 in Q1 2026 per PRLD's latest filing, from $24.9 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $111.3 million in Q2 2023 and troughed at -$41.0 million in Q2 2022.
- A 5-year average of $9.5 million and a median of $37000.0 in 2025 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities sank 9824.17% in 2022, then jumped 73464.71% in 2025.
- Over 5 years, Cash from Financing Activities stood at $155000.0 in 2022, then jumped by 16181.94% to $25.2 million in 2023, then sank by 100.13% to -$34000.0 in 2024, then surged by 73464.71% to $24.9 million in 2025, then slumped by 101.26% to -$314000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$314000.0, $24.9 million, and -$5000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Prelude Therapeutics | 539.17 Mn | 258.54 Mn | - | 85.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 85.82 Mn |
| Mar 31, 2026 | -314,000.00 |
| Dec 31, 2025 | 24.94 Mn |
| Sep 30, 2025 | -5,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Mar 31, 2025 | -160,000.00 |
| Dec 31, 2024 | -34,000.00 |
| Sep 30, 2024 | -131,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Mar 31, 2024 | -14,000.00 |
| Dec 31, 2023 | 25.24 Mn |
| Sep 30, 2023 | 88,000.00 |
| Jun 30, 2023 | 111.34 Mn |
| Mar 31, 2023 | -269,000.00 |
| Dec 31, 2022 | 155,000.00 |
| Sep 30, 2022 | 148,000.00 |
| Jun 30, 2022 | -41.04 Mn |
| Mar 31, 2022 | 41.55 Mn |
| Dec 31, 2021 | 1.95 Mn |
| Sep 30, 2021 | 711,000.00 |